ZA200804489B - 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as PTP-AS inhibitors - Google Patents

1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as PTP-AS inhibitors

Info

Publication number: ZA200804489B
Authority: ZA; South Africa
Prior art keywords: orthofluorophenyl; ptp; inhibitors; substituted; thiazolidinedione derivatives
Prior art date: 2005-12-08

Application number

ZA200804489A

Other languages

English (en)

Inventor

Barnes David

Coppola Gary Mark

Stams Travis

Topiol Sidney Wolf

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-08

Filing date

2008-05-27

Publication date

2009-08-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37903424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200804489(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-27 Application filed by Novartis Ag filed Critical Novartis Ag

2009-08-26 Publication of ZA200804489B publication Critical patent/ZA200804489B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)

ZA200804489A 2005-12-08 2008-05-27 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as PTP-AS inhibitors ZA200804489B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US74849205P	2005-12-08	2005-12-08

Publications (1)

Publication Number	Publication Date
ZA200804489B true ZA200804489B (en)	2009-08-26

Family

ID=37903424

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200804489A ZA200804489B (en)	2005-12-08	2008-05-27	1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as PTP-AS inhibitors

Country Status (23)

Country	Link
US (1)	US8252820B2 (fr)
EP (1)	EP1963293A1 (fr)
JP (1)	JP2009518419A (fr)
KR (1)	KR20080075218A (fr)
CN (1)	CN101336235A (fr)
AR (1)	AR058285A1 (fr)
AU (1)	AU2006321902B2 (fr)
BR (1)	BRPI0619567A2 (fr)
CA (1)	CA2631007A1 (fr)
CR (1)	CR10047A (fr)
EC (1)	ECSP088509A (fr)
GT (1)	GT200800093A (fr)
IL (1)	IL191711A0 (fr)
MA (1)	MA30018B1 (fr)
NO (1)	NO20083030L (fr)
NZ (1)	NZ568663A (fr)
PE (2)	PE20100470A1 (fr)
RU (1)	RU2008127262A (fr)
TN (1)	TNSN08248A1 (fr)
TW (1)	TW200800928A (fr)
UA (1)	UA94921C2 (fr)
WO (1)	WO2007067612A1 (fr)
ZA (1)	ZA200804489B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0619543A2 (pt) *	2005-12-08	2011-10-04	Novartis Ag	derivados de 1,2,5-tiazolidina, composições farmacêuticas contendo os mesmos e referidos usos
BRPI0619547A2 (pt) *	2005-12-08	2011-10-04	Novartis Ag	1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas
WO2007115058A2 (fr) *	2006-03-31	2007-10-11	Novartis Ag	Composés organiques
DE102007015169A1 (de) *	2007-03-27	2008-10-02	Universität des Saarlandes Campus Saarbrücken	17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
CN103201244B (zh) *	2010-08-26	2015-06-17	阿尔比马尔公司	用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
AU2011313191A1 (en)	2010-10-08	2013-05-02	Mochida Pharmaceutical Co., Ltd.	Cyclic amide derivative
EP2683699B1 (fr)	2011-03-08	2015-06-24	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683700B1 (fr)	2011-03-08	2015-02-18	Sanofi	Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
EP2683704B1 (fr)	2011-03-08	2014-12-17	Sanofi	Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120054A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
CA2834465A1 (fr)	2011-04-28	2012-11-01	Mochida Pharmaceutical Co., Ltd.	Derive d'amide cyclique
WO2013045413A1 (fr)	2011-09-27	2013-04-04	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2017078499A2 (fr) *	2015-11-06	2017-05-11	경북대학교 산학협력단	Composition pour la prévention ou le traitement d'une maladie neuroinflammatoire, contenant un inhibiteur de la protéine tyrosine phosphatase
PE20210372A1 (es) *	2018-06-21	2021-02-26	Abbvie Inc	Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
KR20210060514A (ko)	2018-09-18	2021-05-26	바스프 에스이	디아미노트리아진 화합물
MX2021010544A (es) *	2019-03-14	2021-10-01	Calico Life Sciences Llc	Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
JP2023507774A (ja) *	2019-12-18	2023-02-27	カリコライフサイエンシーズエルエルシー	タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
US20240383886A1 (en) *	2019-12-20	2024-11-21	Calico Life Sciences Llc	Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof
JP2023542503A (ja) *	2020-09-11	2023-10-10	カリコライフサイエンシーズエルエルシー	タンパク質チロシンホスファターゼ阻害物質及びその使用方法
KR20230137954A (ko)	2021-01-27	2023-10-05	바스프 에스이	디아미노트리아진 화합물
EP4305030A1 (fr) *	2021-03-11	2024-01-17	Kumquat Biosciences Inc.	Hétérocycles et leurs utilisations
MX2024005656A (es) *	2021-11-11	2024-08-06	Calico Life Sciences Llc	Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
AU2022387106A1 (en) *	2021-11-11	2024-05-23	Abbvie Inc.	Protein tyrosine phosphatase inhibitors and methods of use thereof
AR128379A1 (es)	2022-01-31	2024-04-24	Bristol Myers Squibb Co	Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
EP4472958A1 (fr) *	2022-02-02	2024-12-11	Nerio Therapeutics, Inc.	Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations
CN119137117A (zh) *	2022-02-02	2024-12-13	耐瑞欧医疗公司	蛋白酪氨酸磷酸酶抑制剂及其用途
WO2023150150A1 (fr) *	2022-02-02	2023-08-10	Nerio Therapeutics, Inc.	Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations
WO2024059041A1 (fr) *	2022-09-13	2024-03-21	Kumquat Biosciences, Inc.	N-hétérocycles benzo-fusionnés et leurs utilisations
WO2024067802A1 (fr) *	2022-09-30	2024-04-04	深圳众格生物科技有限公司	Inhibiteur de protéine tyrosine phosphatase, son procédé de préparation et son utilisation pharmaceutique
TW202432118A (zh) *	2022-11-09	2024-08-16	美商必治妥美雅史谷比公司	蛋白質酪胺酸磷酸酶抑制劑、其組合物及使用方法
WO2024137727A1 (fr) *	2022-12-21	2024-06-27	Bristol-Myers Squibb Company	Inhibiteurs de 1,2,4-thiazolidin-3-one-1,1-dioxyde de protéine tyrosine phosphatase, compositions et procédés d'utilisation
WO2024141015A1 (fr) *	2022-12-30	2024-07-04	Insilico Medicine Ip Limited	Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations
CN118852335A (zh) *	2023-04-28	2024-10-29	中科中山药物创新研究院	噻二唑烷酮衍生物及其制备方法和应用
WO2025011570A1 (fr) *	2023-07-11	2025-01-16	深圳众格生物科技有限公司	Inhibiteur de protéine tyrosine phosphatase, composition le comprenant et son utilisation médicale
WO2025016906A1 (fr) *	2023-07-14	2025-01-23	Katholieke Universiteit Leuven	Nouveaux composés pour traiter le cancer et des maladies métaboliques
CN117343052B (zh) *	2023-12-04	2024-02-06	英矽智能科技(上海)有限公司	蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002076439A2 (fr) *	2001-03-23	2002-10-03	The Board Of Trustees Of The University Of Illinois	Composes capables de moduler l'activite de transporteurs de medicaments multiples et leur utilisation therapeutique
PT1492780E (pt) *	2002-04-03	2012-04-11	Novartis Ag	Derivados 5-substituídos de 1,1-dioxo-1,2,5-tiazolidina-3- -ona como inibidores de ptpase 1b
GB0225986D0 (en) *	2002-11-07	2002-12-11	Astrazeneca Ab	Chemical compounds
GB0227813D0 (en)	2002-11-29	2003-01-08	Astrazeneca Ab	Chemical compounds
CA2511818A1 (fr) *	2002-12-30	2004-07-29	Jeffrey O. Saunders	Sulfhydantoines utilisees comme isosteres phosphate
US7135575B2 (en) *	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
WO2005035551A2 (fr) *	2003-10-08	2005-04-21	Incyte Corporation	Inhibiteurs de proteines se liant a des molecules phosphorylees
BRPI0619543A2 (pt)	2005-12-08	2011-10-04	Novartis Ag	derivados de 1,2,5-tiazolidina, composições farmacêuticas contendo os mesmos e referidos usos
BRPI0619547A2 (pt)	2005-12-08	2011-10-04	Novartis Ag	1,1,3-trioxo-1,2,5-tiadiazolidinas, composição farmacêutica e uso das mesmas
UA94724C2 (en)	2005-12-08	2011-06-10	Новартис Аг	Thiadiazolidinone derivatives as antidiabetic agents
WO2007115058A2 (fr)	2006-03-31	2007-10-11	Novartis Ag	Composés organiques

2006
- 2006-06-12 UA UAA200807752A patent/UA94921C2/ru unknown
- 2006-12-06 AR ARP060105391A patent/AR058285A1/es not_active Application Discontinuation
- 2006-12-06 RU RU2008127262/04A patent/RU2008127262A/ru not_active Application Discontinuation
- 2006-12-06 CN CNA2006800524439A patent/CN101336235A/zh active Pending
- 2006-12-06 EP EP06844889A patent/EP1963293A1/fr not_active Withdrawn
- 2006-12-06 WO PCT/US2006/046542 patent/WO2007067612A1/fr active Application Filing
- 2006-12-06 CA CA002631007A patent/CA2631007A1/fr not_active Abandoned
- 2006-12-06 BR BRPI0619567-9A patent/BRPI0619567A2/pt not_active IP Right Cessation
- 2006-12-06 KR KR1020087016433A patent/KR20080075218A/ko not_active Application Discontinuation
- 2006-12-06 NZ NZ568663A patent/NZ568663A/en not_active IP Right Cessation
- 2006-12-06 PE PE2010000301A patent/PE20100470A1/es not_active Application Discontinuation
- 2006-12-06 JP JP2008544464A patent/JP2009518419A/ja active Pending
- 2006-12-06 AU AU2006321902A patent/AU2006321902B2/en not_active Ceased
- 2006-12-06 PE PE2006001572A patent/PE20071094A1/es not_active Application Discontinuation
- 2006-12-06 US US12/096,432 patent/US8252820B2/en not_active Expired - Fee Related
- 2006-12-07 TW TW095145872A patent/TW200800928A/zh unknown
2008
- 2008-05-26 IL IL191711A patent/IL191711A0/en unknown
- 2008-05-27 ZA ZA200804489A patent/ZA200804489B/xx unknown
- 2008-06-02 MA MA30986A patent/MA30018B1/fr unknown
- 2008-06-05 CR CR10047A patent/CR10047A/es not_active Application Discontinuation
- 2008-06-06 EC EC2008008509A patent/ECSP088509A/es unknown
- 2008-06-06 GT GT200800093A patent/GT200800093A/es unknown
- 2008-06-06 TN TNP2008000248A patent/TNSN08248A1/en unknown
- 2008-07-04 NO NO20083030A patent/NO20083030L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2631007A1 (fr)	2007-06-14
PE20071094A1 (es)	2008-01-07
US20100035942A1 (en)	2010-02-11
AR058285A1 (es)	2008-01-30
US8252820B2 (en)	2012-08-28
UA94921C2 (en)	2011-06-25
JP2009518419A (ja)	2009-05-07
IL191711A0 (en)	2008-12-29
AU2006321902A1 (en)	2007-06-14
RU2008127262A (ru)	2010-01-20
TW200800928A (en)	2008-01-01
KR20080075218A (ko)	2008-08-14
MA30018B1 (fr)	2008-12-01
ECSP088509A (es)	2008-07-30
GT200800093A (es)	2010-07-09
TNSN08248A1 (en)	2009-10-30
CN101336235A (zh)	2008-12-31
AU2006321902B2 (en)	2011-11-10
WO2007067612A1 (fr)	2007-06-14
BRPI0619567A2 (pt)	2011-10-04
PE20100470A1 (es)	2010-07-13
NZ568663A (en)	2011-07-29
CR10047A (es)	2008-10-16
NO20083030L (no)	2008-08-28
EP1963293A1 (fr)	2008-09-03

Publication	Publication Date	Title
ZA200804489B (en)	2009-08-26	1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as PTP-AS inhibitors
TWI369351B (en)	2012-08-01	2,4-diamino-pyrimidines as aurora inhibitors
HUS1900034I1 (hu)	2019-07-29	6,7-telítetlen-7-karbamoil-szubsztituált morfinán-származékok
ZA200606974B (en)	2008-04-30	Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
IL192053A0 (en)	2008-12-29	2-adamantylurea derivatives as selective 11??-hsd1 inhibitors
HK1129305A1 (zh)	2009-11-27	取代的 -氨基-吡咯並三嗪衍生物
SG152287A1 (en)	2009-05-29	Acetylene derivatives
IL192033A0 (en)	2008-12-29	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
ZA200804762B (en)	2009-04-29	1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
HUS2000022I1 (hu)	2020-07-28	Tiglien-3-on származékok
EP1878727A4 (fr)	2013-11-13	Dérivés de 2-aminoquinazoline
IL201973A0 (en)	2010-06-16	3,3-spiroindolinone derivatives
PL1954674T3 (pl)	2016-09-30	Nowe pochodne N-fenetylokarboksyamidu
ZA200805411B (en)	2009-07-29	Aryl-isoxazolo-4-yl-oxadiazole derivatives
IL185674A0 (en)	2008-01-06	1-benzylindole-2-carboxamide derivatives
ZA201001797B (en)	2010-11-24	1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
IL195279A0 (en)	2009-08-03	1,5-diphenylpyrazoles ii as hsp90 inhibitors
IL184841A0 (en)	2007-12-03	Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
IL182739A0 (en)	2007-07-24	Acylatednonadepsipeptides used as lysobactin derivatives
ZA200805028B (en)	2009-12-30	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
HK1115878A1 (en)	2008-12-12	(2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors
TWI315670B (en)	2009-10-11	Substituted aryl 1,4-pyrazine derivatives
IL191138A0 (en)	2008-12-29	Pyrazoloisoquinoline derivatives
IL182538A0 (en)	2007-09-20	1,5-diheterocycle-1h-triazole derivative
IL201444A0 (en)	2010-06-16	New 4, 8 - diphenyl - polyazanaphthalene derivatives